Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients

Free Radical Biology and Medicine

Volumn 53, Issue 1, 2012, Pages 160-171

  Yang, Jun ^a   Eiserich, Jason P ^a,b   Cross, Carroll E ^a,b   Morrissey, Brian M ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cystic fibrosis; Free radicals; LC MS MS; Metabolomics; Regulatory lipid mediators; Sputum

Indexed keywords

11 HYDROXYICOSATETRAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 15 HYDROXYICOSATETRAENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 8 HYDROXYARACHIDONIC ACID; 9 HYDROXYICOSATETRAENOIC ACID; EPOXYICOSATRIENOIC ACID; HYDROXYICOSATETRAENOIC ACID; LEUKOTRIENE B4; LIPID; LIPOXIN A; OXYLIPIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; RESOLVIN E1; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LIQUID CHROMATOGRAPHY; LUNG FUNCTION; MALE; METABOLITE; METABOLOMICS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SPUTUM; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION MEDIATORS; MALE; METABOLOMICS; MIDDLE AGED; OXYLIPINS; SPUTUM; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84861712025     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.05.001     Document Type: Article

References (95)

1. J.V. Fahy, and B.F. Dickey Airway mucus function and dysfunction N. Engl. J. Med. 363 2010 2233 2247
2. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N. Engl. J. Med. 352 2005 1992 2001
3. T.S. Blackwell, A.A. Stecenko, and J.W. Christman Dysregulated NF-κB activation in cystic fibrosis: evidence for a primary inflammatory disorder Am. J. Physiol. Lung Cell. Mol. Physiol 281 2001 L69 L70
4. T.E. Machen Innate immune response in CF airway epithelia: hyperinflammatory? Am. J. Physiol. Cell Physiol 291 2006 C218 C230
5. A.M. Jones, and J.M. Helm Emerging treatments in cystic fibrosis Drugs 69 2009 1903 1910
6. G. Doring, and E. Gulbins Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease Cell. Microbiol. 11 2009 208 216
7. M. Bodas, and N. Vij The NF-κB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential Discovery Med 9 2010 346 356
8. M. Cohen-Cymberknoh, D. Shoseyov, and E. Kerem Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life Am. J. Respir. Crit. Care Med. 183 2011 1463 1471
9. J.F. Chmiel, M. Berger, and M.W. Konstan The role of inflammation in the pathophysiology of CF lung disease Clin. Rev. Allergy Immunol. 23 2002 5 27
10. E.J. Saude, P. Lacy, S. Musat-Marcu, D.C. Mayes, J. Bagu, S.F. Man, B.D. Sykes, and R. Moqbel NMR analysis of neutrophil activation in sputum samples from patients with cystic fibrosis Magn. Reson. Med. 52 2004 807 814
11. D.R. Koehler, G.P. Downey, N.B. Sweezey, A.K. Tanswell, and J. Hu Lung inflammation as a therapeutic target in cystic fibrosis Am. J. Respir. Cell Mol. Biol. 31 2004 377 381
12. S.D. Sagel, J.F. Chmiel, and M.W. Konstan Sputum biomarkers of inflammation in cystic fibrosis lung disease Proc. Am. Thorac. Soc 4 2007 406 417
13. H. Heijerman Infection and inflammation in cystic fibrosis: a short review J. Cyst. Fibros. 4 Suppl. 2 2005 3 5
14. A.M. Cantin, T.B. White, C.E. Cross, H.J. Forman, R.J. Sokol, and D. Borowitz Antioxidants in cystic fibrosis: conclusions from the CF antioxidant workshop, Bethesda, Maryland Free Radic. Biol. Med. 42 2007 15 31
15. C. Mueller, S.A. Braag, A. Keeler, C. Hodges, M. Drumm, and T.R. Flotte Lack of cystic fibrosis transmembrane conductance regulator in CD3 lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses Am. J. Respir. Cell Mol. Biol. 44 2011 922 929
16. Ratner, D.; Mueller, C. Immune responses in cystic fibrosis; are they intrinsically defective? Am. J. Respir. Cell Mol. Biol. (in press); 2012.
17. J.M. Collaco, and G.R. Cutting Update on gene modifiers in cystic fibrosis Curr. Opin. Pulm. Med. 14 2008 559 566
18. K.E. McDougal, D.M. Green, L.L. Vanscoy, M.D. Fallin, M. Grow, S. Cheng, S.M. Blackman, J.M. Collaco, L.B. Henderson, K. Naughton, and G.R. Cutting Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis Eur. J. Hum. Genet. 18 2010 680 684
19. F. Stanke, T. Becker, V. Kumar, S. Hedtfeld, C. Becker, H. Cuppens, S. Tamm, J. Yarden, U. Laabs, B. Siebert, L. Fernandez, M. Macek Jr, D. Radojkovic, M. Ballmann, J. Greipel, J.J. Cassiman, T.F. Wienker, and B. Tummler Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia J. Med. Genet. 48 2011 24 31
20. Y. Xu, C. Liu, J.C. Clark, and J.A. Whitsett Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung J. Biol. Chem. 281 2006 11279 11291
21. D.S. Cheng, W. Han, S.M. Chen, T.P. Sherrill, M. Chont, G.Y. Park, J.R. Sheller, V.V. Polosukhin, J.W. Christman, F.E. Yull, and T.S. Blackwell Airway epithelium controls lung inflammation and injury through the NF-κB pathway J. Immunol. 178 2007 6504 6513
22. G. John, A.O. Yildirim, B.K. Rubin, D.C. Gruenert, and M.O. Henke TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells Am. J. Respir. Cell Mol. Biol. 42 2010 424 431
23. P.J. Barnes, and I.M. Adcock Glucocorticoid resistance in inflammatory diseases Lancet 373 2009 1905 1917
24. C. Bonnans, and B.D. Levy Lipid mediators as agonists for the resolution of acute lung inflammation and injury Am. J. Respir. Cell Mol. Biol. 36 2007 201 205
25. F. Karpati, L. Meurling, B. Wretlind, and L. Hjelte Interleukin-8 in sputum from cystic fibrosis patients during ibuprofen treatment M.A. Harrison, Progress in Cystic Fibrosis Research 2005 Nova Sci. Publ Hauppauge, NY 171 183
26. M.W. Konstan, P.J. Byard, C.L. Hoppel, and P.B. Davis Effect of high-dose ibuprofen in patients with cystic fibrosis N. Engl. J. Med. 332 1995 848 854
27. J. Li, Y.Y. Xiang, L. Ye, L.C. Tsui, J.F. Macdonald, J. Hu, and W.Y. Lu Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR Eur. Respir. J. 32 2008 334 343
28. G.Y. Park, and J.W. Christman Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases Am. J. Physiol. Lung Cell. Mol. Physiol 290 2006 L797 L805
29. K. Czerska, A. Sobczynska-Tomaszewska, D. Sands, A. Nowakowska, D. Bak, K. Wertheim, J. Poznanski, J. Zielenski, A. Norek, and J. Bal Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients J. Appl. Genet 51 2010 323 330
30. M. Masoodi, M. Eiden, A. Koulman, D. Spaner, and D.A. Volmer Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks Anal. Chem. 82 2010 8176 8185
31. M.J. Stables, and D.W. Gilroy Old and new generation lipid mediators in acute inflammation and resolution Prog. Lipid Res. 50 2011 35 51
32. C.N. Serhan, Y. Lu, S. Hong, and R. Yang Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins Methods Enzymol. 432 2007 275 317
33. R.A. Navarro-Xavier, J. Newson, V.L. Silveira, S.N. Farrow, D.W. Gilroy, and J. Bystrom A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties J. Immunol. 184 2010 1516 1525
34. D. Takai, T. Nagase, and T. Shimizu New therapeutic key for cystic fibrosis: a role for lipoxins Nature Immunol. 5 2004 357 358
35. T.M. McKeever, S.A. Lewis, H.A. Smit, P. Burney, J.R. Britton, and P.A. Cassano The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function Am. J. Respir. Crit. Care Med. 171 2005 966 971
36. C.N. Serhan Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol 177 2010 1576 1591
37. J.M. Schwab, N. Chiang, M. Arita, and C.N. Serhan Resolvin E1 and protectin D1 activate inflammation-resolution programmes Nature 447 2007 869 874
38. A. Dave, and I.A. Graham Oxylipin signaling: a distinct role for the jasmonic acid precursor cis-()-12-oxo-phytodienoic acid (cis-OPDA) Front. Plant Sci 3 2012 1 6
39. K. Gronert Lipid autacoids in inflammation and injury responses: a matter of privilege Mol. Interv. 8 2008 28 35
40. A.E. Feldstein, R. Lopez, T.A. Tamimi, L. Yerian, Y.M. Chung, M. Berk, R. Zhang, T.M. McIntyre, and S.L. Hazen Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis J. Lipid Res. 51 2010 3046 3054
41. C.M. Spickett, I. Wiswedel, W. Siems, K. Zarkovic, and N. Zarkovic Advances in methods for the determination of biologically relevant lipid peroxidation products Free Radic. Res. 44 2010 1172 1202
42. M. Ollero, G. Astarita, I.C. Guerrera, I. Sermet-Gaudelus, S. Trudel, D. Piomelli, and A. Edelman Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients J. Lipid Res. 52 2011 1011 1022
43. K.A. Massey, and A. Nicolaou Lipidomics of polyunsaturated-fatty-acid- derived oxygenated metabolites Biochem. Soc. Trans. 39 2011 1240 1246
44. A. Higdon Cell signalling by reactive lipid species: new concepts and molecular mechanisms Biochem. J. 442 2012 453 464
45. S.D. Freedman, P.G. Blanco, M.M. Zaman, J.C. Shea, M. Ollero, I.K. Hopper, D.A. Weed, A. Gelrud, M.M. Regan, M. Laposata, J.G. Alvarez, and B.P. OSullivan Association of cystic fibrosis with abnormalities in fatty acid metabolism N. Engl. J. Med. 350 2004 560 569
46. L. Iuliano, R. Monticolo, G. Straface, S. Zullo, F. Galli, M. Boaz, and S. Quattrucci Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis Am. J. Clin. Nutr. 90 2009 477 484
47. W.J. Vaughan, F.T. Lindgren, J.B. Whalen, and S. Abraham Serum lipoprotein concentrations in cystic fibrosis Science 199 1978 783 786
48. J. Carlstedt-Duke, M. Bronnegard, and B. Strandvik Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect Proc. Natl. Acad. Sci. USA 83 1986 9202 9206
49. B. Rhodes, E.F. Nash, E. Tullis, P.B. Pencharz, M. Brotherwood, A. Dupuis, and A. Stephenson Prevalence of dyslipidemia in adults with cystic fibrosis J. Cyst. Fibros. 9 2010 24 28
50. B. Strandvik Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukotrienes Essent Fatty Acids 83 2010 121 129
51. E. Bravo, M. Napolitano, S.B. Valentini, and S. Quattrucci Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis Lipids Health Dis. 9 2010 129
52. S.W. Njoroge Increased Δ5- and Δ6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis Biochim. Biophys. Acta 1811 2011 431 440
53. K.F. Thomsen Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis Lipids 46 2011 669 677
54. S.W. Njoroge DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity J. Lipid Res. 53 2012 257 265
55. J.F. Collawn, L. Fu, and Z. Bebok Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator. Expert Rev Proteomics 7 2010 495 506
56. K.L. Palmer, L.M. Aye, and M. Whiteley Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum J. Bacteriol. 189 2007 8079 8087
57. A.J. Sloane Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects Am. J. Respir. Crit. Care Med. 172 2005 1416 1426
58. B.J. McMorran, S.A. Patat, J.B. Carlin, K. Grimwood, A. Jones, D.S. Armstrong, J.C. Galati, P.J. Cooper, C.A. Byrnes, P.W. Francis, C.F. Robertson, D.A. Hume, C.H. Borchers, C.E. Wainwright, and B.J. Wainwright Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients Clin. Chem. 53 2007 1782 1791
59. J.E. Wolak, C.R. Esther Jr., and T.M. OConnell Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients Biomarkers 14 2009 55 60
60. J. Yang, K. Schmelzer, K. Georgi, and B.D. Hammock Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry Anal. Chem. 81 2009 8085 8093
61. R.J. Knudson, M.D. Lebowitz, C.J. Holberg, and B. Burrows Changes in the normal maximal expiratory flow-volume curve with growth and aging Am. Rev. Respir. Dis. 127 1983 725 734
62. P.A. Flume, B.P. OSullivan, K.A. Robinson, C.H. Goss, P.J. Mogayzel Jr, D.B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, R. Rosenblatt, R.L. Vender, L. Hazle, K. Sabadosa, and B. Marshall Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health Am. J. Respir. Crit. Care Med. 176 2007 957 969
63. A.P. Sampson, D.A. Spencer, C.P. Green, P.J. Piper, and J.F. Price Leukotrienes in the sputum and urine of cystic fibrosis children Br. J. Clin. Pharmacol. 30 1990 861 869
64. M.W. Konstan, R.W. Walenga, K.A. Hilliard, and J.B. Hilliard Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis Am. Rev. Respir. Dis. 148 1993 896 901
65. J.T. Zakrzewski, N.C. Barnes, P.J. Piper, and J.F. Costello Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay Br. J. Clin. Pharmacol. 23 1987 19 27
66. D.W. Reid, N. Misso, S. Aggarwal, P.J. Thompson, and E.H. Walters Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis Respirology 12 2007 63 69
67. J.T. Zakrzewski, N.C. Barnes, J.F. Costello, and P.J. Piper Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease Am. Rev. Respir. Dis. 136 1987 779 782
68. M.F. Moghaddam, D.F. Grant, J.M. Cheek, J.F. Greene, K.C. Williamson, and B.D. Hammock Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase Nat. Med 3 1997 562 566
69. V.T. Vasu, S.J. de Cruz, J.S. Houghton, K.A. Hayakawa, B.M. Morrissey, C.E. Cross, and J.P. Eiserich Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: focus on myeloperoxidase Free Radic. Res. 45 2011 165 176
70. C.W. Moss, S.B. Samuels, and R.E. Weaver Cellular fatty acid composition of selected Pseudomonas species Appl. Microbiol 24 1972 596 598
71. H. Sato, J.B. Feix, C.J. Hillard, and D.W. Frank Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU J. Bacteriol. 187 2005 1192 1195
72. A.M. Saliba, D.O. Nascimento, M.C. Silva, M.C. Assis, C.R. Gayer, B. Raymond, M.G. Coelho, E.A. Marques, L. Touqui, R.M. Albano, U.G. Lopes, D.D. Paiva, P.T. Bozza, and M.C. Plotkowski Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU Cell. Microbiol. 7 2005 1811 1822
73. H. Sato, and D.W. Frank ExoU is a potent intracellular phospholipase Mol. Microbiol. 53 2004 1279 1290
74. H. Sato, D.W. Frank, C.J. Hillard, J.B. Feix, R.R. Pankhaniya, K. Moriyama, V. Finck-Barbancon, A. Buchaklian, M. Lei, R.M. Long, J. Wiener-Kronish, and T. Sawa The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU EMBO J 22 2003 2959 2969
75. T.C. Sorrell, M. Muller, and K. Sztelma Bacterial metabolism of human polymorphonuclear leukocyte-derived arachidonic acid Infect. Immun. 60 1992 1779 1785
76. R.E. Vance, S. Hong, K. Gronert, C.N. Serhan, and J.J. Mekalanos The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase Proc. Natl. Acad. Sci. USA 101 2004 2135 2139
77. D.P. MacEachran, S. Ye, J.M. Bomberger, D.A. Hogan, A. Swiatecka-Urban, B.A. Stanton, and G.A. OToole The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator Infect. Immun. 75 2007 3902 3912
78. E. Martinez, M. Hamberg, M. Busquets, P. Diaz, A. Manresa, and E.H. Oliw Biochemical characterization of the oxygenation of unsaturated fatty acids by the dioxygenase and hydroperoxide isomerase of Pseudomonas aeruginosa 42A2 J. Biol. Chem. 285 2010 9339 9345
79. K.B. Twomey Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa ISME J 6 2012 939 950
80. S. Kitamura, K. Hashizume, T. Iida, E. Miyashita, K. Shirahata, and H. Kase Studies on lipoxygenase inhibitors. II. KF8940 (2-n-heptyl-4- hydroxyquinoline-N-oxide), a potent and selective inhibitor of 5-lipoxygenase, produced by Pseudomonas methanica J. Antibiot. (Tokyo) 39 1986 1160 1166
81. C.D. Bahl, C. Morisseau, J.M. Bomberger, B.A. Stanton, B.D. Hammock, G.A. OToole, and D.R. Madden Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor J. Bacteriol. 192 2010 1785 1795
82. F. Visioli Molecular targets of omega 3 and conjugated linoleic fatty acids - micromanaging cellular response Front. Physiol 3 2012 42
83. H. Seki, K. Fukunaga, M. Arita, H. Arai, H. Nakanishi, R. Taguchi, T. Miyasho, R. Takamiya, K. Asano, A. Ishizaka, J. Takeda, and B.D. Levy The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury J. Immunol. 184 2010 836 843
84. M. Wan, C. Godson, P.J. Guiry, B. Agerberth, and J.Z. Haeggstrom Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1 FASEB J. 25 2011 1697 1705
85. D.N. McMurray, D.L. Bonilla, and R.S. Chapkin n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization Chem. Phys. Lipids 164 2011 626 635
86. C.L. Karp, L.M. Flick, K.W. Park, S. Softic, T.M. Greer, R. Keledjian, R. Yang, J. Uddin, W.B. Guggino, S.F. Atabani, Y. Belkaid, Y. Xu, J.A. Whitsett, F.J. Accurso, M. Wills-Karp, and N.A. Petasis Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway Nat. Immunol. 5 2004 388 392
87. V. Starosta, F. Ratjen, E. Rietschel, K. Paul, and M. Griese Anti-inflammatory cytokines in cystic fibrosis lung disease Eur. Respir. J. 28 2006 581 587
88. S.L. Lundstrom, D. Balgoma, A.M. Wheelock, J.Z. Haeggstrom, S.E. Dahlen, and C.E. Wheelock Lipid mediator profiling in pulmonary disease Curr. Pharm. Biotechnol. 12 2011 1026 1052
89. M.R. Al-Turkmani, S.D. Freedman, and M. Laposata Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukotrienes Essent Fatty Acids 77 2007 309 318
90. S. Van Biervliet Oral DHA supplementation in ΔF508 homozygous cystic fibrosis patients. Prostaglandins Leukotrienes Essent Fatty Acids 78 2008 109 115
91. G. Olveira Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis Arch. Bronconeumol 46 2010 70 77
92. Z. Jiang, X. Yin, and Q. Jiang Natural forms of vitamin E and 13′-carboxychromanol, a long-chain vitamin E metabolite, inhibit leukotriene generation from stimulated neutrophils by blocking calcium influx and suppressing 5-lipoxygenase activity, respectively J. Immunol 186 2011 1173 1179
93. A. Planaguma, M.A. Pfeffer, G. Rubin, R. Croze, M. Uddin, C.N. Serhan, and B.D. Levy Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4 Mucosal Immunol 3 2010 270 279
94. R. Kaddurah-Daouk Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study Metabolomics 6 2010 191 201
95. M.W. Konstan, J.S. Wagener, A. Yegin, S.J. Millar, D.J. Pasta, and D.R. VanDevanter Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint J. Cyst. Fibros. 9 2010 332 338